Epigenetic inactivation of DNA repair genes as promising prognostic and predictive biomarkers in urothelial bladder carcinoma patients

• Published in: Molecular genetics and genomics : MGG Vol. 297; no. 6; pp. 1671 - 1687
• Main Authors: Mohanad, Marwa, Yousef, Hend F., Bahnassy, Abeer A.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.11.2022; Springer Nature B.V
• Subjects: Animal Genetics and Genomics; artificial intelligence; Biochemistry; Biomarkers; Biomedical and Life Sciences; bladder; Bladder cancer; Cancer; carcinoma; Chemotherapy; Cisplatin; data collection; DNA; DNA damage; DNA methylation; DNA repair; drug therapy; Epigenetics; Genes; Genomes; genomics; Human Genetics; Invasiveness; Learning algorithms; Life Sciences; Machine learning; methylation; Microbial Genetics and Genomics; Original; Original Article; Patients; phenotype; Phenotypes; Plant Genetics and Genomics; Polymerase chain reaction; Prediction models; Retina; Retinoblastoma; Tumors; urinary bladder neoplasms; Urothelial cancer; CtIP/RBBP8; Prognosis; Machine-learning predictions of response; MSH4; Urothelial bladder carcinoma; Epigenetic inactivation
• ISSN: 1617-4615; 1617-4623; 1617-4623
• DOI: 10.1007/s00438-022-01950-x

We sought to examine epigenetic inactivation of DNA damage repair (DDR) genes as prognostic and predictive biomarkers for urothelial bladder cancer (UBC) as there are currently no reliable prognostic biomarkers that identify UBC patients who would benefit from chemotherapy. Genome-wide DNA methylome using the cancer genome atlas-bladder cancer (TCGA-BLCA) datasets (primary tumors = 374 and normal tissues = 37) was performed for 154 DDR genes. The most two significant differentially methylated genes, Retinoblastoma binding protein 8 ( RBBP8) and MutS homologue 4 (MSH4) , between primary tumors and normal tissues of TCGA–BLCA were validated by methylation-specific PCR (MSP) in UBC ( n  = 70) compared to normal tissues ( n  = 30). RBBP8 and MSH4 expression was measured using qRT-PCR. We developed a predictive model for therapeutic response based on the RBBP8 - and MSH4 -methylation along with patients’ clinical features . Then, we assessed the prognostic significance of RBBP8 and MSH4 . RBBP8- and MSH4 methylation and corresponding gene downregulation significantly associated with muscle-invasive phenotype, prolonged progression-free survival (PFS) and increased susceptibility to cisplatin chemotherapy in UBC. Promoter methylation of RBBP8 and MSH4 was positively correlated with each other and with their corresponding gene repression. The best machine-learning classification model predicted UBC patients’ response to cisplatin-based chemotherapy with an accuracy of 90.05 ± 4.5%. Epigenetic inactivation of RBBP8 and MSH4 in UBC could sensitize patients to DNA-damaging agents. A predictive machine-learning modeling approach based on the clinical features along with RBBP8- and MSH4 -methylation might be a promising tool for stratification of UBC responders from nonresponders to chemotherapy.